Cart
sales@molnova.com
Elacridar
CAS No. 143664-11-3
Elacridar ( GF-120918;GW-0918;GG-918 )
Catalog No. M11856 CAS No. 143664-11-3
A potent inhibitor of multidrug resistance (MDR) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC50 of 0.02 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 32 | In Stock |
|
| 10MG | 51 | In Stock |
|
| 25MG | 98 | In Stock |
|
| 50MG | 178 | In Stock |
|
| 100MG | 267 | In Stock |
|
| 200MG | 447 | In Stock |
|
| 500MG | 714 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameElacridar
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent inhibitor of multidrug resistance (MDR) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC50 of 0.02 uM.
-
DescriptionA potent inhibitor of multidrug resistance (MDR) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC50 of 0.02 uM; effectively competes with [3H]azidopine for binding P-glycoprotein; restores sensitivity of the tumor to a single dose of doxorubicin in mice; orally bioavailable.Breast Cancer Phase 1 Discontinued
-
SynonymsGF-120918;GW-0918;GG-918
-
PathwayMembrane Transporter/Ion Channel
-
TargetP-glycoprotein
-
RecptorP-gp(P-glycoprotein)
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number143664-11-3
-
Formula Weight563.64
-
Molecular FormulaC34H33N3O5
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCOC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC
-
Chemical Name4-Acridinecarboxamide, N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hyafil F, et al. Cancer Res. 1993 Oct 1;53(19):4595-602.
2. den Ouden D, et al. Leukemia. 1996 Dec;10(12):1930-6.
3. Witherspoon SM, et al. Clin Cancer Res. 1996 Jan;2(1):7-12.
2. den Ouden D, et al. Leukemia. 1996 Dec;10(12):1930-6.
3. Witherspoon SM, et al. Clin Cancer Res. 1996 Jan;2(1):7-12.
molnova catalog
related products
-
Valspodar
A highly potent multidrug-resistance modifier that acts as a P-glycoprotein inhibitor.
-
Zosuquidar trihydroc...
A potent P-glycoprotein (P-gp) inhibitor with Ki of 60 nM.
-
Tariquidar
A potent, specific P-gp inhibitor with Kd of 5.1 nM.
